NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback